Previous close | 0.0300 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0800 |
Strike | 47.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0300 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 30 |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials supporting ongoing regulatory reviews. The volume of data being presented by Astellas reinforces its commitment to changing the cou
Amazon, Visa, Pfizer, Martin Marietta Materials and Zimmer Biomet are included in this Analyst Blog.